Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700578 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL1270224 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL5011536 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL29752854 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL7807533 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL4752182 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL9951538 | 1.00 | SMPD1 (0.44) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| Monoethanolamine SCHEMBL27957871 | 0.93 | SMPD1 (0.41) | SMPD1ENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL190586 | 0.92 | LPAR1 (0.49) | ENPP2LPAR6LPAR1LPAR4LPAR5 | |
| SCHEMBL29910363 | 0.92 | LPAR1 (0.49) | ENPP2LPAR6LPAR1LPAR4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973935-B2 | Stabilized nanobubbles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-04-13 | — | — | US | claimed |
| US-20200061220-A1 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-10434194-B2 | PSMA targeted nanobubbles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-10-08 | — | — | US | claimed |
| US-10357575-B2 | Stabilized nanobubbles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-23 | — | — | US | claimed |
| US-20190175766-A1 | STABILIZED CROSSLINKED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | UNIV CASE WESTERN RESERVE (US) | 2019-06-13 | — | — | US | claimed |
| US-20180064831-A1 | PSMA TARGETED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-08 | — | — | US | claimed |
| WO-2017210612-A1 | STABILIZED CROSSLINKED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-12-07 | — | — | WO | claimed |
| US-20140147390-A1 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-29 | — | — | US | claimed |
| WO-2012040710-A2 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-03-29 | — | — | WO | claimed |
| WO-2023133539-A1 | SYSTEMS AND METHODS OF GENERATING LIPID, PROTEIN, AND/OR PROTEIN SHELLED BUBBLES | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230092885-A1 | TARGETED NANOBUBBLE THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| EP-4117674-A1 | TARGETED NANOBUBBLE THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2023278893-A1 | ADOPTIVE IMMUNOTHERAPY COMPOSITIONS AND METHODS OF TRACKING | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021183931-A1 | TARGETED NANOBUBBLE THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20050123593-A1 | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints | THOMPSON JONATHAN (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1406571-A2 | LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHRITIC JOINTS | Depuy International Limited (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003017978-A1 | METHOD OF MANUFACTURING LIPOSOMES | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003000190-A2 | LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHRITIC JOINTS | DEPUY (GB) | 2003-01-03 | — | — | WO | disclosed |
| US-20020119188-A1 | Method of manufacturing liposomes | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020001613-A1 | Method of manufacturing liposomes | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434194-B2 | PSMA targeted nanobubbles for diagnostic and therapeutic applications | PHOSPHO1, PSMA1, PSMA2 | SMPD1 172/4885ENPP2 932/4885LPAR6 83/4885 |
| US-20180064831-A1 | PSMA TARGETED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | PHOSPHO1, PSMA1, PSMA2 | SMPD1 172/4885ENPP2 932/4885LPAR6 83/4885 |
| US-20020119188-A1 | Method of manufacturing liposomes | LIPA, CLPTM1L, MGLL | SMPD1 71/4885ENPP2 290/4885LPAR6 16/4885 |
| US-20230092885-A1 | TARGETED NANOBUBBLE THERAPY | BAX, CASP3, BCL2 | SMPD1 1430/4885ENPP2 837/4885LPAR6 1122/4885 |
| US-20020001613-A1 | Method of manufacturing liposomes | LIPA, CLPTM1L, SGMS1 | SMPD1 60/4885ENPP2 976/4885LPAR6 36/4885 |
| US-20050123593-A1 | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints | CD44, LPCAT1, MMP7 | SMPD1 168/4885ENPP2 52/4885LPAR6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.